Professor Thushan de Silva
MBChB BSc (Hons) DTM&H MRCP FRCPath PhD
School of Medicine and Population Health
Professor of Infectious Diseases
Honorary Consultant Physician in Infectious Diseases
+44 114 215 9532
Full contact details
School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
I am an Infectious Diseases Clinician Scientist with a programme of research centred around clinical discovery science in the UK and Africa. Our group applies a broad range of methods including human immunology, epidemiology, molecular diagnostics and genomics, to establish how pathogens interact with human hosts at population and individual levels. We work primarily on respiratory viruses such as influenza and SARS-CoV-2, and Streptococcus pyogenes (Group A Streptococcus), investigating the natural history of infection and immunity to inform the design of diagnostic tools, vaccines, and other preventative measures. A specific area of interest is also how immunocompromising conditions such as HIV and haematopoietic stem cell transplantation impact the clinical risk and vaccine-induced immunity to respiratory viruses.
I am part of the Clinical Infection Research Group (CIRG) in the Medical School at the University of Sheffield and am an Honorary Consultant Physician in Infectious Diseases in the South Yorkshire Regional Department of Infection and Tropical Medicine in Sheffield. I am co-director of the and lead the host-pathogen interactions theme. I am also a Principal Investigator in the Vaccines and Immunity Theme at the Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine.
I completed my undergraduate medical training at the University of Bristol in 2000. Following postgraduate clinical training in General Internal Medicine, Infectious Diseases and HIV in Oxford and London, I moved to Sheffield for higher specialist training in Infectious Diseases & Microbiology in 2004. After relocating to The MRC Unit The Gambia in 2007, I was awarded a British Infection Society Research Fellowship (2007-8), followed by a MRC Clinical Research Training Fellowship and PhD (2008 – 11) under the supervision of and , to study the pathogenesis of HIV-2 infection and the molecular epidemiology of HIV-1 and HIV-2 in West Africa.
I joined the University of Sheffield in 2013 as an NIHR Academic Clinical Lecturer in Infectious Diseases & Microbiology. I was awarded a Wellcome Trust Intermediate Clinical Fellowship (2016 -2021), based between Imperial College London and the MRC Unit The Gambia, to study the immunogenicity of intranasal Live Attenuated Influenza Vaccine in children and bidirectional interactions with nasopharyngeal microbiota. I returned to the University of Sheffield as a Senior Clinical Lecturer in 2020 and led a programme of SARS-CoV-2 research through the COVID-19 pandemic, including roles as lead PI in Sheffield for the and the study. I was awarded an MBE in 2021 for services to COVID-19 research.
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- . Nature Communications, 16.
- . Nature Medicine, 31(10), 3360-3371.
- . Journal of Clinical Investigation, 135(18).
- . Journal of Infection, 91(2), 106546-106546.
- . British Journal of Haematology, 205(6), 2206-2218.
- . The Lancet Microbe, 5(7), 679-688.
- . Nature Communications, 15(1).
- . Nature Communications, 14(1).
- . Nature Medicine, 29(7), 1760-1774.
- . Journal of Infection, 86(1), 1-8.
- . Frontiers in Immunology, 13.
- . CELL REPORTS MEDICINE, 3(2).
- . Nature Communications, 13(1).
- . The Lancet Microbe, 3(1), e21-e31.
- . The Journal of Infectious Diseases, 225(10), 1750-1754.
- . iScience, 24(11).
- . Cell, 184(23), 5699-5714.e11.
- . The Lancet Microbe, 2(12), e656-e665.
- . Cell Host & Microbe, 29(1), 23-31.e4.
- . Cell, 182(4), 812-827.e19.
- . PLOS Neglected Tropical Diseases, 13(10).
- . Proceedings of the National Academy of Sciences, 116(34), 17121-17126.
- . The Lancet Respiratory Medicine, 7(8), 665-676.
- . Lancet Infectious Diseases, 19(4), e110-e119.
- . Journal of Immunological Methods, 449, 1-6.
- . Blood, 121(21), 4330-4339.
- . Journal of Virology, 86(2), 930-946.
All publications
Journal articles
- . Journal of Infection.
- . PLoS Computational Biology, 21(9).
- . Nature Communications, 16.
- . Nature Medicine, 31(10), 3360-3371.
- . Bone Marrow Transplantation.
- . Journal of Infection, 91(3), 106570-106570.
- . Journal of Clinical Investigation, 135(18).
- . Journal of Infection, 91(2), 106546-106546.
- . iScience, 28(7), 112893-112893.
- . Communications Medicine, 5(1).
- . The Journal of Infectious Diseases, 232(3), 550-559.
- . Nature Communications, 16.
- . Leukemia, 39, 1547-1557.
- . The Lancet Infectious Diseases, 25(8), 909-924.
- . Nature Communications, 16(1).
- . Journal of Infection, 90(4).
- . The Lancet Microbe, 6(3), 100971-100971.
- . Journal of Immunological Methods, 536, 113786-113786.
- . The Journal of Infectious Diseases, 231(1), e28-e37.
- . Microbial Genomics, 10(12).
- . British Journal of Haematology, 205(6), 2206-2218.
- . Scientific Reports, 14(1).
- . EMBO Molecular Medicine, 16(11), 2882-2917.
- . Microbial Genomics, 10(8).
- . Vaccine: X, 20, 100546-100546.
- . iScience, 27(9), 110626-110626.
- . Biochemical Journal, 481(11), 669-682.
- . The Lancet Microbe, 5(7), 679-688.
- . Cell Reports Medicine, 5(5), 101553-101553.
- . The Lancet Rheumatology, 6(6), e339-e351.
- . Nature Communications, 15(1).
- . Clinical and Experimental Immunology, 218(1), 78-92.
- . Nature Immunology, 25(4), 607-621.
- . PLOS Global Public Health, 4(3).
- . BMJ Open, 14(2).
- . Journal of Immunological Methods, 526, 113618-113618.
- . The Journal of Infectious Diseases, 230(1), e17-e29.
- . npj Digital Medicine, 6.
- . Clinical Infection in Practice, 20(Supplement 1).
- . Wellcome Open Research, 8.
- . mBio, 14(5).
- . Nature Communications, 14(1).
- . Nature Medicine, 29(7), 1760-1774.
- . The Lancet Global Health, 11(7), e1075-e1085.
- . Journal of Hospital Infection, 139, 23-32.
- . iScience, 26(7).
- . Communications Medicine, 3(1).
- . The Journal of Infectious Diseases, 228(7), 957-965.
- . Genome Biology, 24(1).
- . Cell Reports, 42(4).
- . Gates Open Research, 6.
- . Med, 4(3), 191-215.e9.
- . The Lancet Global Health, 11(3), e414-e424.
- . PLoS Medicine, 20(1).
- . Wellcome Open Research, 8.
- . Nature Reviews Microbiology, 21(3), 162-177.
- . eBioMedicine, 87.
- . Cell Reports, 42(1).
- . mSphere, 8(1).
- . Journal of Infection, 86(1), 1-8.
- . Journal of Hospital Infection, 131, 34-42.
- . Gates Open Research, 6.
- . eLife, 11.
- . Frontiers in Immunology, 13.
- . Virus Evolution, 8(2).
- . eBioMedicine, 83.
- . Virus Evolution, 8(2).
- . Epidemiology and Infection, 150.
- . Communications Biology, 5.
- . Methods and Protocols, 5(4).
- . Wellcome Open Research, 6.
- . Open Forum Infectious Diseases, 9(5).
- . BMJ Open, 12(4).
- . Journal of the American Society of Nephrology, 33(5), 883-887.
- . Journal of Hospital Infection, 126, 21-28.
- . Virus Evolution, 8(1), 1-14.
- . Nature Communications, 13(1).
- . Wellcome Open Research, 6.
- . Nat Commun, 13(1), 1013.
- . CELL REPORTS MEDICINE, 3(2).
- . Nature Communications, 13(1).
- . Frontiers in Immunology, 12.
- . BMC Infectious Diseases, 22(1).
- . The Lancet Microbe, 3(1), e21-e31.
- . The Journal of Infectious Diseases, 225(10), 1750-1754.
- . Cell Reports Medicine, 2(12).
- . iScience, 24(11).
- . Cell, 184(23), 5699-5714.e11.
- . Journal of Infection, 83(6), 693-700.
- . Frontiers in Microbiology, 12.
- . The Lancet Microbe, 2(12), e656-e665.
- . Journal of Medical Virology, 94(1), 161-172.
- . BMJ Open Respiratory Research, 8.
- . Pathogens and Immunity, 6(2), 27-49.
- . Vaccine, 39(34), 4778-4783.
- . The Lancet, 398(10296), 223-237.
- . Sri Lanka Journal of Medicine, 30(1), 4-8.
- . eLife, 10.
- . Emerging Infectious Diseases, 27(8), 2064-2072.
- . The Lancet Microbe, 2(8), e354-e365.
- . Journal of Clinical Microbiology, 59(6).
- . Nature Communications, 12(1).
- . International Journal of Infectious Diseases, 105, 579-587.
- . Genome Research, 31(4), 645-658.
- . Vaccines, 9(2).
- . Cell, 184(5), 1171-1187.e20.
- . Journal of Hospital Infection, 110, 103-107.
- . Cell Host & Microbe, 29(1), 23-31.e4.
- . Microbial Genomics, 7(1).
- . Journal of Infection, 82(1), 159-198.
- . Nature Immunology, 21(11), 1336-1345.
- . Cell, 182(4), 812-827.e19.
- . The Lancet Microbe, 1(3), e99-e100.
- . Thorax, 75(8), 621-622.
- . Wellcome Open Research, 5.
- . Pediatric Infectious Disease Journal, 39(10), 925-930.
- . Clinical Infectious Diseases, 70(10), 2235-2236.
- . Eurosurveillance, 25(14).
- . Scientific Reports, 9(1).
- . PLOS Neglected Tropical Diseases, 13(10).
- . Clinical Infectious Diseases, 69(Supplement_2), S105-S113.
- . Proceedings of the National Academy of Sciences, 116(34), 17121-17126.
- . The Lancet Respiratory Medicine, 7(8), 665-676.
- . Frontiers in Cellular and Infection Microbiology, 9.
- . Frontiers in Cellular and Infection Microbiology, 9.
- . Lancet Infectious Diseases, 19(4), e110-e119.
- . Vaccine, 37(3), 452-457.
- . Journal of Virology, 93.
- . Journal of Antimicrobial Chemotherapy, 73(8), 2197-2200.
- . AIDS, 32(6), 709-714.
- . Vaccine, 36(13), 1772-1780.
- . Journal of Immunological Methods, 449, 1-6.
- . Lancet Global Health, 5(3).
- . Bone Marrow Transplant.
- . Ocular Oncology and Pathology, 3, 17-21.
- . Scientific Reports, 6.
- . AIDS, 29(18), 2479-2486.
- . Tissue Antigens, 86(3), 220-221.
- . Tissue Antigens, 86(4), 312-313.
- . Tissue Antigens, 86(2), 150-151.
- . Tissue Antigens, 86(1), 70-71.
- . Tissue Antigens, 85(2), 153-154.
- . Tissue Antigens, 85(2), 151-152.
- . Journal of Infection, 70(3), 314-316.
- . Tissue Antigens, 84(6), 595-596.
- . Tissue Antigens, 84(6), 596-597.
- . Tissue Antigens, 84(6), 594-595.
- . Tissue Antigens, 84(5), 521-522.
- . Tissue Antigens, 84(5), 520-521.
- . Tissue Antigens, 84(4), 427-429.
- . The Journal of Immunology, 192(12), 5802-5812.
- . Journal of Infection, 68(4), 397-399.
- . Tissue Antigens, 83(4), 305-306.
- . Tissue Antigens, 83(2), 126-127.
- . Journal of Infection, 67(4), 344-344.
- . Blood, 121(21), 4330-4339.
- . AIDS, 27(1), 125-134.
- . N Engl J Med, 367(20), 1962.
- . New England Journal of Medicine, 367(20), 1961-1963.
- . PLoS Pathogens, 8(7).
- . PLoS ONE, 7(6).
- . PLoS Neglected Tropical Diseases, 6(6).
- . AIDS Research and Human Retroviruses, 28(6), 584-590.
- . Blood, 119(9), 2083-2092.
- . Journal of Virology, 86(2), 930-946.
- . BMC Research Notes, 4.
- . PLoS ONE , 6(12).
- . AIDS, 25(17), 2167-2175.
- . Retrovirology, 8(S1).
- . Retrovirology, 8(S1).
- . AIDS Research and Treatment, 2011.
- HIV-2 goes global: An unaddressed issue in Indian anti-retroviral programmes. Indian Journal of Medical Research, 132(12), 660-662.
- . Retrovirology, 7.
- . Vaccine, 28, B60-B67.
- . HIV Therapy, 4(3), 305-323.
- . Clinical Infectious Diseases, 48(12), 1790-1793.
- . Journal of Infection, 57(5), 426-427.
- . Trends in Microbiology, 16(12), 588-595.
- . PLOS MEDICINE, 5(5), 721-724.
- . Journal of Infection, 55(3), e67-e68.
- . Journal of Infection, 55(3), e58-e58.
- . Mayo Clinic proceedings, 82(9), 1103-1116.
- . Journal of Infection, 54(4), e207-e210.
- . Journal of Clinical Pathology, 59(11), 1226.1-1226.
- . Journal of Clinical Microbiology, 44(12), 4628-4629.
- . International Journal of STD & AIDS, 17(7), 495-497.
- . Journal of Infection.
- . Journal of Infection.
- . Journal of Infection, 52(4), e113-e116.
- . Journal of Neurology, Neurosurgery & Psychiatry, 76(8), 1074-1074.
- . Sexually Transmitted Infections, 81(3), 276-277.
- . Nature Medicine.
- . Nature Communications, 15(1).
- The impact of an updated pandemic H1N1 strain on shedding and immunogenicity to Russian-backbone live attenuated influenza vaccine among children in The Gambia: an open-label, observational, phase 4 study. The Lancet Respiratory Medicine.
- . BMJ OPEN, 8(8).
- . PLoS Medicine, 5(6), e134-e134.
- Poor Antibody Responses to SARS-CoV-2 Infection or Vaccination Are Associated With High Re-Infection Rates in Haemodialysis and Renal Transplant Patients.
- Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial.
- Co-Infections, Secondary Infections, and Antimicrobial Usage in Hospitalised Patients with COVID-19 from the ISARIC WHO CCP-UK Study: A Prospective, Multicentre Cohort Study.
- Pre-Existing Upregulation of Interferon Pathways in the Nasopharynx Impacts Viral Shedding Following Live Attenuated Influenza Vaccine Challenge in Children.
- Characterisation of SARS-CoV-2 Membrane Protein-Specific Antibodies as an Additional Serological Target Following COVID-19 Infections Identified Through a High Content Microscopy-Based Platform.
- Streptococcus Pyogenes Carriage and Infection within Households in the Gambia: A Longitudinal Cohort Study.
- SARS-CoV-2 Incidence and Re-Infection During Delta and Omicron Ba.1 Waves in the Gambia: Results from a Prospective Household Cohort Study in a Population with Low SARS-CoV-2 Vaccine Coverage.
- Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial.
Book chapters
- , Infectious Diseases (pp. xv-xxxvi). Elsevier
- , Infectious Diseases (pp. 133-135.e1). Elsevier
- , Models of Protection Against HIV/SIV (pp. 293-315). Elsevier
- , Models of Protection Against HIV/SIV (pp. xi-xii). Elsevier
Conference proceedings
- . Bone Marrow Transplantation, Vol. 52(Suppl 1) (pp S269-S270). Marseille, France, 26 March 2017 - 26 March 2017.
- Routine Vaccination Programme (RVP) Practice after Adult and Paediatric Allogeneic Haematopoietic Stem Cell Transplant (HSCT): A British Society of Blood and Marrow Transplantation (BSBMT) Survey of UK NHS-Based Programmes. BONE MARROW TRANSPLANTATION, Vol. 51 (pp S400-S401)
- A study of adherence to a vaccination schedule following adult allogenic haematopoietic stem cell transplants in UK transplant centre. BONE MARROW TRANSPLANTATION, Vol. 50 (pp S203-S204)
Preprints
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Springer Science and Business Media LLC.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Springer Science and Business Media LLC.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Springer Science and Business Media LLC.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- , Cold Spring Harbor Laboratory.
- Genomic Surveillance of SARS-CoV-2 in Ghana: Leveraging an Integrated National Influenza and SARS-CoV-2 Platform.
- Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort Study.
- .
- .
- .
- .
- .
- .
- .
- .
- .
- .
- Teaching interests
-
I am involved in delivering the undergraduate (MBChB) Infectious Diseases, Tropical Medicine and Microbiology curriculum at the University of Sheffield. I also lecture on the MSc in Antimicrobial Resistance (MED404), Molecular Medicine MSc (MED6006) and Pharmacology of Respiratory Disease (CDL302, Biomedical Science).
- Professional activities and memberships
-
National and International
- British Infection Association Scientific and Research Secretary (2023 - )
- Wellcome Trust Early Career Award Interview Committee, Infection and Immunobiology (2022 - )
- Africa Research Excellence Fund () College of Experts (2022 - )
- Chair, Vaccines Subcommittee, British Society of Blood and Marrow Transplantation and cellular therapy (BSBMTCt), vaccination subcommittee (2023 - )
- Associate Editor, Journal of Infection (2019 - )
Local
- Co-Director, Florey Institute of Infection (2023 - )
- Director of CL3 suite, Medical School, University of Sheffield (2022 - )
- UREC Ethics reviewer for Medical School (2022 -)
- University of Sheffield Biosafety Committee (2019 -)
- Research themes and key projects
Mucosal and systemic immunity to respiratory viruses
- Hybrid immunity to SARS-CoV-2 in Zimbabwean adults with HIV and other chronic diseases (Bill and Melinda Gates Foundation, 2023 – 2026). Key collaborators: , , .
- Study of SARS-CoV-2 systemic and mucosal immunity within a household transmission study in The Gambia (UKRI). Key collaborators: , .
- Study of SARS-CoV-2 T-cell and antibody responses as part of the , and consortium (2024 – 2028).
- Part of a consortium to establish a (Chan Zuckerberg Initiative, 2021 – 2025).
- Supervisor for Dr. Ben Lindsey, Wellcome Trust 4ward North Clinical PhD fellowship on inflammatory memory in the upper respiratory tract following respiratory viral infections (2023 – 2026).
Epidemiology of respiratory viruses
- Surveillance for SARS-CoV-2 and other respiratory viruses by establishment of a sentinel surveillance platform for influenza-like illness in The Gambia, along with a household transmission cohort (TransVir) with , , Dr. Abdul Karim Sesay.
- University of Sheffield lead for the (COG-UK), using Oxford Nanopore Technology (ONT) to sequence SARS-CoV-2 isolates in South Yorkshire. Building on our group’s sequencing expertise gained during this project, we are now focusing on optimising ONT-based assays with direct utility in NHS diagnostic microbiology and virology laboratories. This aligns work with key deliverables our group are leading within the Infection and Immunity Theme of .
The epidemiology and immune responses to Streptococcus pyogenes
Several clinical and molecular epidemiology studies forming part of the MRC Unit The Gambia Strep A research portfolio, with (School of Biosciences), (LSHTM) and (MRC Gambia).
- Co-supervisor for three Wellcome Trust Clinical PhD Training Fellows in Global Health (Dr. Edwin Armitage, Dr. Alex Keeley, Dr Ed Monk) who are using the platform of a household and school transmission studies to explore transmission and natural immunity to S. pyogenes.
- Co-lead at the MRC Gambia in a global network of scientists seeking to define correlates of immune protection in natural infection with Streptococcus pyogenes (iSpy Network, 2023 - 2027).
- Lead for immunology studies across UoS and MRC Gambia in a Wellcome Trust funded S. pyogenes human challenge study to establish correlates of protection (2025 – 2027).